Overview
flowchart TD
Psilocybin_Therapy_for_Depress["Psilocybin Therapy for Depression in Parkinsons "]
Psilocybin_Therapy_for_Depress["Phase"]
Psilocybin_Therapy_for_Depress -->|"related to"| Psilocybin_Therapy_for_Depress
style Psilocybin_Therapy_for_Depress fill:#81c784,stroke:#333,color:#000
Psilocybin_Therapy_for_Depress["trial"]
Psilocybin_Therapy_for_Depress -->|"related to"| Psilocybin_Therapy_for_Depress
style Psilocybin_Therapy_for_Depress fill:#81c784,stroke:#333,color:#000
Psilocybin_Therapy_for_Depress["investigates"]
Psilocybin_Therapy_for_Depress -->|"related to"| Psilocybin_Therapy_for_Depress
style Psilocybin_Therapy_for_Depress fill:#81c784,stroke:#333,color:#000
style Psilocybin_Therapy_for_Depress fill:#4fc3f7,stroke:#333,color:#000
This Phase 2 clinical trial investigates psilocybin as a novel treatment for depression in Parkinson's Disease (PD) patients. Depression is one of the most common non-motor symptoms in PD, affecting up to 50% of patients throughout the disease course. This trial represents a cutting-edge approach to addressing this unmet clinical need through psychedelic-assisted therapy.
Trial Details
...Overview
Mermaid diagram (expand to render)
This Phase 2 clinical trial investigates psilocybin as a novel treatment for depression in Parkinson's Disease (PD) patients. Depression is one of the most common non-motor symptoms in PD, affecting up to 50% of patients throughout the disease course. This trial represents a cutting-edge approach to addressing this unmet clinical need through psychedelic-assisted therapy.
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06455293 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | To be confirmed |
| Collaborators | To be confirmed |
| Intervention | Psilocybin |
| Purpose | Treatment of depression in PD |
| Study Type | Interventional |
| Estimated Enrollment | 40-60 participants |
| Study Design | Randomized, double-blind, placebo-controlled |
Mechanism of Action
Psilocybin exerts its therapeutic effects through multiple interconnected mechanisms:
5-HT2A Receptor Agonism
Psilocybin is a prodrug that is metabolized to psilocin, its active form. Psilocin acts as a partial agonist at serotonin 5-HT2A receptors, which are densely distributed in the prefrontal cortex and other brain regions involved in mood regulation. This receptor activation leads to:
- Enhanced cortical plasticity — 5-HT2A activation promotes dendritic spine growth and synaptogenesis
- Altered network connectivity — Restructuring of brain network patterns associated with depression
- Reduced amygdala reactivity — Decreased threat processing and emotional reactivity
Default Mode Network Modulation
The default mode network (DMN) is hyperactive in depression and anxiety states. Psilocybin has been shown to:
- Temporarily disrupt DMN connectivity — Allowing for new patterns of thought and emotional processing
- Increase global brain connectivity — Enabling novel integrations of emotional experience
- Promote "network reset" — Long-lasting changes in brain network organization
Neuroplasticity Effects
Research has demonstrated that psilocybin promotes neuroplasticity through:
- Increased dendritic spine density in prefrontal cortex neurons
- Enhanced expression of brain-derived neurotrophic factor (BDNF)
- Improved functional connectivity between frontal and limbic regions
- Anti-inflammatory effects potentially relevant to PD neuropathology
Depression in Parkinson's Disease
Prevalence and Impact
Depression is the most common neuropsychiatric complication in PD:
- Affects 30-50% of all PD patients
- Can precede motor symptoms by years
- Significantly impacts quality of life
- Associated with faster disease progression
- Increases caregiver burden and disability
Challenges with Current Treatments
Standard antidepressants face limitations in PD:
| Treatment | Limitations in PD |
|-----------|-------------------|
| SSRIs | May worsen motor symptoms; delayed onset |
| SNRIs | Similar limitations; side effect burden |
| TCAs | Anticholinergic effects; cardiac toxicity |
| Dopamine agonists | May cause impulse control disorders |
Why Psilocybin May Help
Psilocybin offers several potential advantages for PD depression:
Non-dopaminergic mechanism — Does not directly affect dopaminergic neurons lost in PD
Rapid onset — Potential for faster antidepressant effects than traditional medications
Durable effects — Single or few doses may provide lasting benefits
Addresses treatment resistance — Novel mechanism for patients unresponsive to SSRIs
Potential neuroprotective effects — 5-HT2A activation may have anti-inflammatory properties relevant to PD pathologyStudy Design
Intervention Protocol
The trial employs a rigorous design:
- Randomized, double-blind, placebo-controlled structure
- Single or dual psilocybin administrations in a supportive setting
- Integration sessions with trained therapists before and after psilocybin exposure
- Follow-up period to assess durability of effects
Therapeutic Framework
Psychedelic-assisted therapy combines:
Preparation session — Patient education and expectation setting
Dosing session — Supervised psilocybin administration in comfortable setting
Integration session — Processing the experience and identifying insights
Follow-up — Long-term monitoring of mood and PD symptomsSafety Considerations
Key safety measures for PD patients:
- Careful cardiac monitoring (PD patients may have autonomic dysfunction)
- Exclusion of patients with psychosis history (risk of PD psychosis)
- Monitoring for drug interactions with PD medications
- Assessment of impulse control behaviors
Outcome Measures
Primary Endpoints
| Measure | Description |
|---------|-------------|
| Change in depression scores | Assessed using validated scales (e.g., BDI, MADRS) |
| Response rate | Percentage achieving clinically significant improvement |
| Remission rate | Proportion achieving symptom remission |
Secondary Endpoints
| Measure | Description |
|---------|-------------|
| Motor symptom stability | UPDRS motor scores to ensure no worsening |
| Quality of life | PDQ-39 and general quality of life measures |
| Anxiety symptoms | GAD-7 or similar |
| Cognitive function | MoCA and neuropsychological testing |
| Sleep quality | PDSS and general sleep scales |
| Duration of effect | Long-term follow-up of antidepressant response |
Clinical Significance
This trial represents several important firsts:
First Phase 2 trial of psilocybin specifically for PD depression
Novel treatment paradigm for a common, difficult-to-treat non-motor symptom
Mechanistic exploration of 5-HT2A agonism in the context of neurodegeneration
Potential practice-changing approach if efficacy is demonstratedBroader Implications
If successful, this trial could:
- Establish psilocybin as a treatment option for PD depression
- Encourage research into other psychedelic compounds for neurodegenerative diseases
- Highlight the importance of treating non-motor symptoms in PD
- Advance understanding of the gut-brain axis and serotonin in PD
Serotonin Dysfunction in PD
Parkinson's Disease involves multiple neurotransmitter systems beyond dopamine:
- Serotonin neuron loss — 5-HT neurons in the raphe nuclei are affected in PD
- Reduced serotonin transmission — Contributes to depression and anxiety
- 5-HT2A receptor changes — Altered receptor expression in PD brains
- Connection to Lewy bodies — Serotonergic neurons may contain alpha-synuclein inclusions
Neuroinflammation Connection
PD involves chronic neuroinflammation, and psilocybin may address this through:
- 5-HT2A-mediated anti-inflammatory effects in glial cells
- Modulation of microglial activation
- Reduced pro-inflammatory cytokine production
- Potential disease-modifying implications
- [Parkinson's Disease](/genes/ar)
- [Depression in Neurodegeneration](/diseases/neurodegeneration)
- [Serotonin Signaling](/mechanisms/serotonin-signaling)
- Non-Motor Symptoms in PD
- 5-HT2A Receptor
- [Dorsal Raphe Nuclei](/cell-types/dorsal-raphe)
- [Psychedelics in Neurology](/genes/cs)
- [Alpha-Synuclein](/mechanisms/alpha-synuclein)
- [BDNF Therapy](/therapeutics/bdnf-therapy)
Mechanism of Action
5-HT2A Receptor Agonism
Psilocybin's therapeutic effects in depression are primarily mediated through its activation of serotonin 5-HT2A receptors[@nichols2016]. Upon ingestion, psilocybin is converted to psilocin, which exhibits high affinity for 5-HT2A receptors as a partial agonist[@rickli2016]. This activation leads to downstream effects including:
- Increased glutamate release in prefrontal cortex[@halberstadt2011]
- Enhanced neuroplasticity through BDNF signaling[@ly2018]
- Reduced default mode network (DMN) activity[@carhartharris2014]
- Altered emotional processing networks[@kraehenmann2015]
Relevance to Parkinson's Disease Depression
Depression in PD is thought to involve both dopaminergic and serotonergic dysfunction[@burn2012]. While PD primarily affects dopaminergic neurons in the substantia nigra, serotonergic systems are also compromised, particularly in advanced disease[@politis2015]. The 5-HT2A receptor-mediated effects of psilocybin may address this serotonergic deficit while also promoting neural plasticity that could benefit motor and non-motor symptoms[@froland2022].
Trial Design
Study Population
The trial targets patients with:
- Confirmed Parkinson's Disease diagnosis
- Clinically significant depression (typically HAM-D score ≥ 17)
- Stable PD medication regimen
- No history of psychosis
Treatment Approach
Psilocybin therapy for depression in PD typically involves[@carhartharris2016]:
- Low to moderate doses (10-25mg psilocybin)
- Supportive therapeutic setting with trained facilitators
- Integration sessions following the psychedelic experience
- Multiple treatment sessions over several weeks
Potential Benefits and Risks
Benefits
Psilocybin-assisted therapy has shown promise for treatment-resistant depression in general populations[@griffiths2016]. Potential benefits for PD patients include:
- Rapid-onset antidepressant effects
- Long-lasting benefits from single or few treatments
- Potential improvement in both mood and motor symptoms
- Addressing depression that responds poorly to conventional antidepressants
Risks and Considerations
Safety considerations include[@johnson2016]:
- Potential for transient anxiety or confusion during treatment
- Risk of psychosis in susceptible individuals
- Possible interactions with PD medications
- Need for careful screening and medical supervision
Connection to Non-Motor Symptoms
Depression in PD significantly impacts quality of life and may accelerate disease progression[@schapira2017]. Treating depression may also improve:
- Cognitive function
- Sleep quality
- Motor symptom perception
- Caregiver burden
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, Nichols, D.E. (2016). Psychedelics (2016)
Rickli, A. et al., (2016). Receptor binding profiles of psychoactive substances (2016)
Unknown, Halberstadt, A.L. & Geyer, M.A. (2011). Multiple receptors contribute to the behavioral effects of hallucinogens (2011)
Ly, C. et al., (2018). Psychedelics promote structural and functional neural plasticity (2018)
Carhart-Harris, R.L. et al., (2014). The entropic brain: a theory of conscious states (2014)
Kraehenmann, R. et al., (2015). Psilocybin induces changes in emotional processing (2015)
Unknown, Burn, D.J. (2012). Depression in Parkinson's disease (2012)
Unknown, Politis, M. & Niccolini, F. (2015). Serotonin in Parkinson's disease (2015)
Froland, L. et al., (2022). Psilocybin and Parkinson's disease (2022)
Carhart-Harris, R.L. et al., (2016). Psilocybin for treatment-resistant depression (2016)
Griffiths, R.R. et al., (2016). Psilocybin produces substantial antidepressant effects (2016)
Johnson, M.W. et al., (2016). Psychedelics as medicine (2016)
Schapira, A.H.V. et al., (2017). Non-motor features of Parkinson's disease (2017)